Neurologic and cognitive sequelae after SARS-CoV2 infection: Different impairment for ICU patients.
COVID-19
Cognitive impairment
Follow up
Intensive care unit
Journal
Journal of the neurological sciences
ISSN: 1878-5883
Titre abrégé: J Neurol Sci
Pays: Netherlands
ID NLM: 0375403
Informations de publication
Date de publication:
15 01 2022
15 01 2022
Historique:
received:
18
10
2021
revised:
16
11
2021
accepted:
18
11
2021
pubmed:
12
12
2021
medline:
8
1
2022
entrez:
11
12
2021
Statut:
ppublish
Résumé
The exact incidence of neurological and cognitive sequelae of COVID-19 in the long term is yet unknown. The aim of this research is to investigate the type of neurological and cognitive impairment in COVID-19 cases of different severity. Two hundred fifteen patients, who had developed COVID-19, were examined 4 months after the diagnosis by means of neurological exam and extensive cognitive evaluation, investigating general cognition, memory, verbal fluency, visuospatial abilities and executive functions. Fifty-two of them were treated in intensive care unit (ICU patients), whereas 163 were not hospitalized (non-ICU patients). Neurological deficits were found in 2/163 (1.2%) of non-ICU and in 7/52 (13.5%) of the ICU cases, all involving the peripheral nervous system. ICU patients performed significantly worse in all the neuropsychological tests and showed a worse age- and education-corrected cognitive impairment: Cognitive Impairment Index (CII) was higher in ICU than in non-ICU patients (median ICU 3 vs 2, p = .001). CII significantly correlated with age in both groups, was unrelated to length of follow- up, diabetes and hypertension and - only for ICU patients- to PaO
Identifiants
pubmed: 34894422
pii: S0022-510X(21)02763-5
doi: 10.1016/j.jns.2021.120061
pmc: PMC8620095
pii:
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
120061Informations de copyright
Copyright © 2021. Published by Elsevier B.V.
Références
N Engl J Med. 2020 Aug 6;383(6):590-592
pubmed: 32402155
Soc Sci Med. 2021 Jan;268:113426
pubmed: 33199035
J Neurol. 2021 Dec;268(12):4422-4428
pubmed: 33932157
Lancet Neurol. 2021 Apr;20(4):247
pubmed: 33743226
Schizophr Res. 2004 Jun 1;68(2-3):283-97
pubmed: 15099610
Ann Clin Transl Neurol. 2021 May;8(5):1073-1085
pubmed: 33755344
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
JAMA. 2021 Apr 20;325(15):1525-1534
pubmed: 33729425
JAMA Netw Open. 2021 May 3;4(5):e2112131
pubmed: 33974053
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
J Clin Psychol. 1984 May;40(3):785-7
pubmed: 6746989
Brain. 1999 Jul;122 ( Pt 7):1341-8
pubmed: 10388799
Crit Care. 2015 May 05;19:220
pubmed: 25939482
MMWR Morb Mortal Wkly Rep. 2020 Jul 31;69(30):993-998
pubmed: 32730238
Arch Gen Psychiatry. 1983 Jul;40(7):812
pubmed: 6860082
Nat Rev Neurol. 2020 Nov;16(11):636-644
pubmed: 32839585
Neurol Sci. 2002 Mar;22(6):443-7
pubmed: 11976975
Lancet Infect Dis. 2021 Aug;21(8):1062-1064
pubmed: 34153235
Brain. 2021 May 7;144(4):1263-1276
pubmed: 33822001
Clin Transl Sci. 2020 Nov;13(6):1077-1086
pubmed: 32315487
N Engl J Med. 2013 Oct 3;369(14):1306-16
pubmed: 24088092
Ann Neurol. 2020 Jul;88(1):1-11
pubmed: 32506549
N Engl J Med. 2020 Sep 3;383(10):989-992
pubmed: 32530583
Cell Rep Med. 2021 May 18;2(5):100288
pubmed: 33969321
JAMA. 2020 Nov 3;324(17):1723-1724
pubmed: 33031513
Curr Neurol Neurosci Rep. 2021 Feb 14;21(3):9
pubmed: 33586020
Curr Opin Neurol. 2021 Jun 1;34(3):417-422
pubmed: 33852526